# A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

Source: https://onco.cc/trials/nct06311721/  
OnCo record `nct06311721` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by Amgen, active and no longer recruiting.

## Summary

A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer is a phase 3 interventional study registered as NCT06311721 by Amgen, with 315 participants enrolled, started 2024-09-09 and due to reach its primary completion in 2028-01-10. Interventions recorded: ABP 234, Pembrolizumab (US), Pembrolizumab (EU). Conditions listed: Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06311721
- Phase: 3
- Setting: A Randomized, Double-Blind Study to Compare Efficacy, Pharmacokinetics, Safety, and Immunogenicity Between ABP 234 and Keytruda® (Pembrolizumab) in Subjects With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
- Sponsor: Amgen
- Enrolled: 315

## Sources

- ClinicalTrials.gov NCT06311721: https://clinicaltrials.gov/study/NCT06311721

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [Amgen](https://onco.cc/companies/amgen/)

---
JSON: https://onco.cc/api/v1/entities/nct06311721.json